Innovator国际已开发动力缓冲主动型ETF-3月 IMAR 深 沪
等待开盘 07-02 09:30:00 美东时间
30.31
-0.135
-0.44%
华盛通- 最 高30.41
- 今 开30.41
- 成交量 11.18万股
- 最 低 30.30
- 昨 收 30.445
- 总市值 1.14亿
- 52周最高 30.75
- 市盈率 静 --
- 换手率 2.98%
- 52周最低 27.77
- 委 比 -33.33%
- 总股本 375.00万
- 历史最高 30.75
- 量 比 14.63
- 振 幅 0.36%
- 历史最低 24.6018
- 每 手 1
- 风险率 0.73%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Genmab Announces Positive Phase 3 Results For Epcoritamab Plus Lenalidomide
BRIEF-Genmab Announces Positive Phase 3 Results For Epcoritamab Plus Lenalidomide June 30 (Reuters) - Genmab A/S GMAB.CO : ANNOUNCES POSITIVE PHASE 3 RESULTS FOR EPCORITAMAB PLUS LENALIDOMIDE IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA, DEMONSTRATING STATISTICALLY SIGNIFICANT
06-30 14:22
UPDATE 1-Mamdani's power play worked. Takeaways from Tuesday’s primaries
UPDATE 1-Mamdani's power play worked. Takeaways from Tuesday’s primaries Updates after results Mamdani succeeds in moving Democrats to the left Vulnerable Republican Lawler will face a ‘Hellcat’ in November Trump covers his endorsement bets in South Carolina By Nolan D. McCaskill WASHINGTON, June 23
06-24 11:34
CPP Investments to invest $740 million in India's CtrlS Datacenters
CPP Investments to invest $740 million in India's CtrlS Datacenters June 17 - Canada Pension Plan Investment Board (CPP Investments) said on Wednesday that it would partner with India's CtrlS Datacenters by investing 70 billion rupees ($740.54 million) in the company and related projects. Here are s
06-17 18:41
BRIEF-Intellia Therapeutics Reports Additional Positive Phase 3 Results For Lonvoguran Ziclumeran (Lonvo-Z)
BRIEF-Intellia Therapeutics Reports Additional Positive Phase 3 Results For Lonvoguran Ziclumeran (Lonvo-Z) June 13 (Reuters) - Intellia Therapeutics Inc NTLA.O : INTELLIA THERAPEUTICS REPORTS ADDITIONAL POSITIVE PHASE 3 RESULTS FOR LONVOGURAN ZICLUMERAN (LONVO-Z) IN PATIENTS WITH HEREDITARY ANGIOED
06-13 19:38
UPDATE 1-Meta ties up with Ambani's Reliance for AI data center in India
UPDATE 1-Meta ties up with Ambani's Reliance for AI data center in India Adds details in paragraphs 3,4; background in paragraphs 5,6 June 10 (Reuters) - Facebook-parent Meta META.O said on Wednesday that it has tied up with Indian billionaire Mukesh Ambani's Reliance Industries RELI.NS for the U.S.
06-10 11:14
BRIEF-GSK To Acquire Nuvalent For $10.6 Billion
BRIEF-GSK To Acquire Nuvalent For $10.6 Billion June 9 (Reuters) - GSK plc GSK.L : GSK PLC - GSK ENTERS AGREEMENT TO ACQUIRE NUVALENT, INC. GSK - ANNOUNCES AGREEMENT TO BUY NUVALENT FOR $10.6 BILLION GSK: ACQUISITION EXPECTED TO BE ACCRETIVE TO SALES AND CORE OPERATING PROFIT IN 2027 GSK - TO BUY N
06-09 14:05
Lockheed Martin shows off counter-drone system in live-fire test
Lockheed Martin (LMT) said Wednesday it intercepted an attack drone during a live-fire test using a system that combines radar sensors, command-and-control software and a containerized missile launche...
06-04 06:01
GIC-backed Asia Healthcare eyes IPO within 12-18 months, cautious on market volatility
GIC-backed Asia Healthcare eyes IPO within 12-18 months, cautious on market volatility By Rishika Sadam and Haripriya Suresh BENGALURU, June 2 (Reuters) - Asia Healthcare Holdings (AHH) is considering listing its shares within the next 12 to 18 months, although it remains wary of market volatility,
06-02 16:13
BRIEF-Grail Reports Full Results From Nhs-Galleri Trial Demonstrating Substantial Reduction In Stage Iv Cancer Diagnoses
BRIEF-Grail Reports Full Results From Nhs-Galleri Trial Demonstrating Substantial Reduction In Stage Iv Cancer Diagnoses May 30 (Reuters) - Grail Inc GRAL.O : GRAIL REPORTS FULL RESULTS FROM NHS-GALLERI TRIAL DEMONSTRATING SUBSTANTIAL REDUCTION IN STAGE IV CANCER DIAGNOSES AT 2026 ASCO ANNUAL MEETIN
05-30 20:14
BRIEF-Immunome Says Varegacestat Treatment Resulted In Statistically Significant Improvements In Primary And All Key Secondary Efficacy Endpoints
BRIEF-Immunome Says Varegacestat Treatment Resulted In Statistically Significant Improvements In Primary And All Key Secondary Efficacy Endpoints May 30 (Reuters) - Immunome Inc IMNM.O : IMMUNOME - VAREGACESTAT TREATMENT RESULTED IN STATISTICALLY SIGNIFICANT IMPROVEMENTS IN PRIMARY AND ALL KEY SECON
05-30 20:12
